4//SEC Filing
BONIUK MILTON 4
Accession 0001214659-18-006488
CIK 0001379006other
Filed
Oct 10, 8:00 PM ET
Accepted
Oct 11, 5:22 PM ET
Size
23.9 KB
Accession
0001214659-18-006488
Insider Transaction Report
Form 4
BONIUK MILTON
Director
Transactions
- Exercise/Conversion
Common Stock, par value $0.001 per share
2018-05-21+5,500,000→ 6,862,648 total(indirect: By IRA) - Exercise/Conversion
Common Stock, par value $0.001 per share
2017-02-21+1,746,288→ 2,776,793 total(indirect: Held by Boniuk Interests, Ltd. () - Award
Common Stock, par value $0.001 per share
2017-07-11+120,744→ 1,362,648 total(indirect: By IRA) - Exercise/Conversion
10% Coupon Series C Convertible Debenture
2018-05-21$5000000.00/sh→ 0 total(indirect: By IRA)Exercise: $5.25From: 2018-06-30→ Common Stock (5,500,000 underlying) - Award
Common Stock, par value $0.001 per share
2017-02-21+153,611→ 1,092,426 total(indirect: By IRA) - Award
Common Stock, par value $0.001 per share
2017-05-04+149,478→ 1,241,904 total(indirect: By IRA) - Exercise/Conversion
8% Coupon Series B Convertible Debenture
2017-02-21$2000000.00/sh→ 0 total(indirect: Held by Boniuk Interests, Ltd.)Exercise: $1.00From: 2017-01-31→ Common Stock (1,746,288 underlying) - Award
Series A Conv Pref Stock, par value $0.001 per share
2018-05-21+150,000→ 337,500 total(indirect: By IRA)Exercise: $0.00→ Common Stock (525,000 underlying)
Holdings
- 823,428
Common Stock, par value $0.001 per share
Footnotes (13)
- [F1]Pursuant to the Conversion and Settlement Agreement, dated as of February 8, 2017 (the "Series B Debenture Conversion Agreement"), between the Issuer and Boniuk Interests, Ltd. (the "Partnership"), on February 21, 2017 the Issuer issued to the Partnership 1,746,288 shares of Common Stock in connection with the Issuer's conversion into shares of Common Stock of the Issuer's 8% Coupon Series B Convertible Debenture due January 31, 2017 (the "Series B Debenture"), including the entire $2,000,000 principal amount plus unpaid interest through the stated maturity date.
- [F10]The securities reported in this row include 194,857 shares of Common Stock held directly by the Reporting Person and 628,571 shares of Common Stock held jointly by the Reporting Person and his spouse.
- [F11]There is no expiration date for the Series B Debenture, the Series C Debenture or the Series A Convertible Preferred Stock.
- [F12]Each share of Series A Convertible Preferred Stock is convertible by the holder into 3.5 shares of Common Stock upon a change of control of the Issuer, as defined in the certificate of designation relating to the Series A Convertible Preferred Stock.
- [F13]Pursuant to the Series C Debenture Redemption Agreement, the Issuer issued to the IRA 150,000 shares of Series A Convertible Preferred Stock, as consideration for the IRA's waiver of certain rights under the Series C Debenture.
- [F2]The effective price per share of Common Stock issued pursuant to the Series B Debenture Conversion Agreement was approximately $1.15.
- [F3]The securities reported in this row are held by the Partnership, a Texas limited partnership. The Reporting Person, as the managing general partner of the Partnership, may be deemed the beneficial owner of such securities for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act").
- [F4]The Issuer issued such shares to the Milton Boniuk IRA (the "IRA") in payment of quarterly interest due on the Issuer's 10% Coupon Series C Convertible Debenture due June 30, 2018 (the "Series C Debenture"), at an effective price of approximately $1.08 per share of Common Stock.
- [F5]The securities reported in this row are held by the IRA. The Reporting Person, as the owner and beneficiary of the IRA, may be deemed the beneficial owner of such securities for purposes of Section 16(a) of the Exchange Act.
- [F6]The Issuer issued such shares to the IRA in payment of quarterly interest due on the Series C Debenture, at an effective price of approximately $1.11 per share of Common Stock.
- [F7]The Issuer issued such shares to the IRA in payment of quarterly interest due on the Series C Debenture, at an effective price of approximately $1.38 per share of Common Stock.
- [F8]Pursuant to the Debenture Redemption Agreement, dated as of November 13, 2017 (the "Series C Debenture Redemption Agreement"), between the Issuer and the IRA, on May 21, 2018 the Issuer issued to the IRA 5,500,000 shares of Common Stock in connection with the Issuer's redemption in full of the Series C Debenture, including the entire $5,000,000 principal amount plus unpaid interest of $500,000 through the stated maturity date.
- [F9]The effective price per share of Common Stock issued pursuant to the Series C Debenture Redemption Agreement was $1.00.
Documents
Issuer
NANOVIRICIDES, INC.
CIK 0001379006
Entity typeother
Related Parties
1- filerCIK 0001580568
Filing Metadata
- Form type
- 4
- Filed
- Oct 10, 8:00 PM ET
- Accepted
- Oct 11, 5:22 PM ET
- Size
- 23.9 KB